276 related articles for article (PubMed ID: 16931107)
1. Cytokines in breast cancer.
Nicolini A; Carpi A; Rossi G
Cytokine Growth Factor Rev; 2006 Oct; 17(5):325-37. PubMed ID: 16931107
[TBL] [Abstract][Full Text] [Related]
2. Changes in cytokine production of breast cancer patients treated with interferons.
Barak V; Kalickman I; Nisman B; Farbstein H; Fridlender ZG; Baider L; Kaplan A; Stephanos S; Peretz T
Cytokine; 1998 Dec; 10(12):977-83. PubMed ID: 10049522
[TBL] [Abstract][Full Text] [Related]
3. Cytokines in the management of high risk or advanced breast cancer: an update and expectation.
Carpi A; Nicolini A; Antonelli A; Ferrari P; Rossi G
Curr Cancer Drug Targets; 2009 Dec; 9(8):888-903. PubMed ID: 20025599
[TBL] [Abstract][Full Text] [Related]
4. Cytokines in lung cancer.
Chyczewska E; Mróz RM
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():8-22. PubMed ID: 9337519
[TBL] [Abstract][Full Text] [Related]
5. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy.
Nicolini A; Carpi A; Rossi G
Cancer Lett; 2007 Jun; 251(2):330-8. PubMed ID: 17215077
[TBL] [Abstract][Full Text] [Related]
6. New developments in the use of cytokines for cancer therapy.
Maini A; Morse PD; Wang CY; Jones RF; Haas GP
Anticancer Res; 1997; 17(5B):3803-8. PubMed ID: 9427784
[TBL] [Abstract][Full Text] [Related]
7. Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia.
Lissoni P; Brivio F; Fumagalli L; Messina G; Secreto G; Romelli B; Fumagalli G; Rovelli F; Colciago M; Brera G
In Vivo; 2007; 21(4):647-50. PubMed ID: 17708360
[TBL] [Abstract][Full Text] [Related]
8. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.
Vazquez-Martin A; Colomer R; Menendez JA
Eur J Cancer; 2007 May; 43(7):1117-24. PubMed ID: 17379503
[TBL] [Abstract][Full Text] [Related]
9. Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin.
Premkumar VG; Yuvaraj S; Vijayasarathy K; Gangadaran SG; Sachdanandam P
Basic Clin Pharmacol Toxicol; 2007 Jun; 100(6):387-91. PubMed ID: 17516992
[TBL] [Abstract][Full Text] [Related]
10. [Cytokines and the liver in health and disease].
Kolarski V; Todorov A; Petrova D
Vutr Boles; 2000; 32(1):19-24. PubMed ID: 11195192
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral cytokines and tumor cell biology determine spontaneous breast cancer-specific immune responses and their correlation to prognosis.
Domschke C; Schuetz F; Ge Y; Seibel T; Falk C; Brors B; Vlodavsky I; Sommerfeldt N; Sinn HP; Kühnle MC; Schneeweiss A; Scharf A; Sohn C; Schirrmacher V; Moldenhauer G; Momburg F; Beckhove P
Cancer Res; 2009 Nov; 69(21):8420-8. PubMed ID: 19843863
[TBL] [Abstract][Full Text] [Related]
13. [Interleukin-21, new adjuvant for cancer therapy?].
Iannello A; Ahmad A
Med Sci (Paris); 2009 Apr; 25(4):341-3. PubMed ID: 19409182
[No Abstract] [Full Text] [Related]
14. Survival impact of integrative cancer care in advanced metastatic breast cancer.
Block KI; Gyllenhaal C; Tripathy D; Freels S; Mead MN; Block PB; Steinmann WC; Newman RA; Shoham J
Breast J; 2009; 15(4):357-66. PubMed ID: 19470134
[TBL] [Abstract][Full Text] [Related]
15. Enhancing the efficacy of hormonal agents with selected targeted agents.
Johnston SR
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
[TBL] [Abstract][Full Text] [Related]
16. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: radiobiological and immunologic strategies].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Jun; 180(6):331-9. PubMed ID: 15175867
[TBL] [Abstract][Full Text] [Related]
17. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.
Roy V; Perez EA
Breast Cancer Res Treat; 2009 Jul; 116(1):31-8. PubMed ID: 19101790
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer: beyond the cutting edge.
Higa GM
Expert Opin Pharmacother; 2009 Oct; 10(15):2479-98. PubMed ID: 19761355
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial.
Pierga JY; Bidard FC; Mathiot C; Brain E; Delaloge S; Giachetti S; de Cremoux P; Salmon R; Vincent-Salomon A; Marty M
Clin Cancer Res; 2008 Nov; 14(21):7004-10. PubMed ID: 18980996
[TBL] [Abstract][Full Text] [Related]
20. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer.
Orlando L; Cardillo A; Rocca A; Balduzzi A; Ghisini R; Peruzzotti G; Goldhirsch A; D'Alessandro C; Cinieri S; Preda L; Colleoni M
Anticancer Drugs; 2006 Sep; 17(8):961-7. PubMed ID: 16940806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
